4.8 Article

Loss of ZnT8 function protects against diabetes by enhanced insulin secretion

期刊

NATURE GENETICS
卷 51, 期 11, 页码 1596-+

出版社

NATURE PUBLISHING GROUP
DOI: 10.1038/s41588-019-0513-9

关键词

-

资金

  1. Welcome Trust [203141]
  2. University of Helsinki
  3. Folkhalsan Research Foundation
  4. Sigrid Juselius Foundation
  5. Academy of Finland [263401, 267882, 312063, 312072, 317599]
  6. EU (EXGENESIS) [EUFP7-MOSAIC FP7-600914]
  7. Ollqvist Foundation
  8. Swedish Cultural Foundation in Finland
  9. Finnish Diabetes Research Foundation
  10. Foundation for Life and Health in Finland
  11. Signe and Ane Gyllenberg Foundation
  12. Finnish Medical Society
  13. Paavo Nurmi Foundation
  14. Helsinki University Central Hospital Research Foundation
  15. Perklen Foundation
  16. Narpes Health Care Foundation
  17. Ministry of Education in Finland, Municipal Heath Care Center and Hospital in Jakobstad
  18. Pfizer Inc.
  19. Regeneron Genetics Center LLC
  20. Hjelt Foundation
  21. Rhapsody
  22. Vinnova (Sweden's Innovation Agency) [2015-01549]
  23. Swedish Diabetes Foundation
  24. Albert Pahlsson Foundation
  25. Crafoord Foundation
  26. Royal Physiographic Society in Lund
  27. Swedish Foundation for Strategic Research [IRC15-0067]
  28. Swedish Research Council [2009-1039, Dnr: 2017-02688]
  29. Pahlsson Foundation
  30. Diabetes Research Foundation
  31. Italian Ministry of University and Research [PRIN 2015373Z39_004]
  32. University of Parma Research Funds
  33. Wellcome Trust Senior Investigator Award [WT098424AIA]
  34. MRC Programme grants [MR/R022259/1, MR/J0003042/1, MR/L020149/1]
  35. Experimental Challenge Grant (DIVA) [MR/L02036X/1]
  36. MRC [MR/N00275X/1]
  37. Diabetes UK [BDA/11/0004210, BDA/15/0005275, BDA 16/0005485]
  38. Imperial Confidence in Concept grants
  39. Royal Society Wolfson Research Merit Award
  40. Wellcome Trust [203141, 095101, 200837, 098381, 106130, 090531]
  41. Medical Research Council [MR/L020149/1]
  42. European Union Horizon 2020 Programme (T2D Systems)
  43. NIH [U01-DK105535, U01-DK085545]
  44. National Institute for Health Research (NIHR) Oxford Biomedical Research Centre
  45. Biocenter Finland
  46. Ahokas Foundation
  47. Hjelt Foundations
  48. Ministry of Education in Finland, Health Care Center in Vasa
  49. Ministry of Education in Finland, Health Care Centers in Narpes
  50. Ministry of Education in Finland, Health Care Centers in Korsholm
  51. Nordic Center of Excellence in Disease Genetics
  52. Vinnova [2015-01549] Funding Source: Vinnova
  53. Medical Research Council [MR/N00275X/1] Funding Source: researchfish
  54. Academy of Finland (AKA) [317599, 317599] Funding Source: Academy of Finland (AKA)
  55. BBSRC [BB/J015873/1] Funding Source: UKRI
  56. MRC [MR/N020472/1, MR/L02036X/1, MR/R022259/1, G0801995, MR/N00275X/1, MR/R010676/1, MR/M012646/1, MR/L020149/1, MR/K001981/1] Funding Source: UKRI

向作者/读者索取更多资源

A rare loss-of-function allele p.Arg138* in SLC30A8 encoding the zinc transporter 8 (ZnT8), which is enriched in Western Finland, protects against type 2 diabetes (T2D). We recruited relatives of the identified carriers and showed that protection was associated with better insulin secretion due to enhanced glucose responsiveness and proinsulin conversion, particularly when compared with individuals matched for the genotype of a common T2D-risk allele in SLC30A8, p.Arg325. In genome-edited human induced pluripotent stem cell (iPSC)-derived beta-like cells, we establish that the p.Arg138* allele results in reduced SLC30A8 expression due to haploinsufficiency. In human beta cells, loss of SLC30A8 leads to increased glucose responsiveness and reduced K-ATP channel function similar to isolated islets from carriers of the T2D-protective allele p.Trp325. These data position ZnT8 as an appealing target for treatment aimed at maintaining insulin secretion capacity in T2D.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据